An Assay for Rapid and Sensitive Flu Virus Detection

Information

  • Research Project
  • 7530062
  • ApplicationId
    7530062
  • Core Project Number
    R43AI077117
  • Full Project Number
    1R43AI077117-01A1
  • Serial Number
    77117
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    8/15/2008 - 16 years ago
  • Project End Date
    7/31/2009 - 15 years ago
  • Program Officer Name
    SALOMON, RACHELLE
  • Budget Start Date
    8/15/2008 - 16 years ago
  • Budget End Date
    7/31/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/15/2008 - 16 years ago
Organizations

An Assay for Rapid and Sensitive Flu Virus Detection

[unreadable] DESCRIPTION (provided by applicant): The specific aims of this Phase I SBIR proposal are to determine the feasibility of a novel detection technology for rapid and sensitive detection of influenza virus. Specifically, we will determine if the manual assay is rapid (about 15 minutes), sensitive (as least 100 times as good as, or better than, an FDA approved antigen test in terms of TCID50 units/mL), reproducible (with CV<15%) and specific (without false positive results from potentially interfering bacterial species at concentrations of upto106 cfu/mL). There are five specific aims in the proposed studies, including: [unreadable] [unreadable] 1. Synthesis, purification and qualification of luciferin - 4,7-di-methyl-O-neuraminic acid substrate - Section D1. Our goal is to obtain at least 1 gram of highly purified substrate (>98% purity by HPLC). [unreadable] [unreadable] 2. Formulation of the detection mix - Section D2. We will prepare a detection mix that contains all necessary reagents for detection of flu viral neuraminidase. The detection mix will be lyophilized in a single-use detection tube. [unreadable] [unreadable] 3. Assay optimization - Section D3 [unreadable] [unreadable] 4. Evaluation of analytical performance - Section D4. Analytical performance of the assay will be evaluated. We will determine the analytical sensitivity for more than 10 strains of human influenza A and human influenza B. [unreadable] [unreadable] 5. Comparison studies and preliminary evaluation using human samples - Section D5. We will perform comparison studies using FDA-approved antigen-based test and RT-PCR assay. In addition, we will test some samples collected from human subjects. [unreadable] [unreadable] PUBLIC HEALTH RELVANCE The proposed Phase I SBIR project will evaluate the feasibility of a novel detection technology for rapid and sensitive detection of influenza virus. The technology simplifies the detection process by using a master mix which enables one-step detection, i.e., addition of a sample to the master mix followed by light signal measurement, all performed in the same detection tube. The entire process takes 10-15 minutes. Successful development of the proposed influenza virus test will provide a better alternative for rapid flu diagnosis, thereby significantly improving our medical capability for interpandemic influenza and potential pandemic influenza. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    196100
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:196100\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CELLEX, INC.
  • Organization Department
  • Organization DUNS
    141314521
  • Organization City
    ROCKVILLE
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20850
  • Organization District
    UNITED STATES